what are glp 1 receptor agonist medicines Top GLP-1 Agonists Balance Weight Loss Efficacy, Safety Overview of GLP-1 Receptor Agonists

[Accessed on 23.11.2014]

Existing data suggest that the effects of GLP-1 on adipose tissue are primarily indirect

February 2026: There are currently 37 pending lawsuits in MDL-3163, which represents people alleging eye injuries from Wegovy and other GLP-1 drugs

10.1016/j.dsx.2024.103067 81

Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)

Obesity Management in adults: a review